Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) EBITDA (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of EBITDA data on record, last reported at -$10.1 million in Q3 2025.

  • For Q3 2025, EBITDA rose 74.57% year-over-year to -$10.1 million; the TTM value through Sep 2025 reached -$42.3 million, up 24.58%, while the annual FY2023 figure was -$27.4 million, 37.28% up from the prior year.
  • EBITDA reached -$10.1 million in Q3 2025 per CRVS's latest filing, down from -$7.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $15.2 million in Q1 2025 and bottomed at -$39.6 million in Q3 2024.
  • Average EBITDA over 4 years is -$8.8 million, with a median of -$7.8 million recorded in 2023.
  • Peak YoY movement for EBITDA: tumbled 551.85% in 2024, then skyrocketed 353.4% in 2025.
  • A 4-year view of EBITDA shows it stood at -$9.2 million in 2022, then soared by 32.76% to -$6.2 million in 2023, then plummeted by 541.09% to -$39.6 million in 2024, then soared by 74.57% to -$10.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$10.1 million in Q3 2025, -$7.9 million in Q2 2025, and $15.2 million in Q1 2025.